Pacemaker and Implantable Cardioverter-Defibrillator Use in a US Myotonic Dystrophy Type 1 Population
Authors:
- 28 October 2011
- journal article
- research article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 22 (12) , 1369-1375
Abstract
Pacemakers and ICDs in Myotonic Dystrophy. Introduction: We assessed implant rates, indications, characteristics, and outcomes in patients with the neuromuscular disease, myotonic dystrophy type 1 (DM1) receiving a pacemaker or an implantable cardioverter‐defibrillator (ICD). Methods and Results: Device use was evaluated in a prospective, multicenter registry of 406 genetically confirmed adult patients followed for 9.5 ± 3.2 years. Forty‐six (11.3%) had or received a pacemaker and 21 (5.2%) received an ICD. Devices were primarily implanted for asymptomatic conduction abnormalities and left ventricular (LV) systolic dysfunction. However, 7 (15.2%) pacemakers were implanted for third‐degree atrioventricular block and 6 (28.6%) ICDs were implanted for ventricular tachyarrhythmias (ventricular tachycardia [VT] or fibrillation [VF]). Patients receiving devices were older and more frequently had heart failure, LV systolic dysfunction, atrial tachyarrhythmias, and ECG conduction abnormalities compared to nondevice patients. Five (10.9%) pacemaker patients underwent upgrade to an ICD, 3 for LV systolic dysfunction, 1 for VT/VF, and 1 for progressive conduction disease. Seventeen (27.4%) of the 62 patients with devices were pacemaker‐dependent at last follow‐up. Three (14.3%) ICD patients had appropriate therapies. Twenty‐four (52.2%) pacemaker patients died including 13 of respiratory failure and 7 of sudden death. Seven (33.3%) ICD patients died including 2 of respiratory failure and 3 of sudden death. The patients with ICDs and sudden death all had LV systolic dysfunction and 1 death was documented due to inappropriate therapies. Conclusions: DM1 patients commonly receive antiarrhythmia devices. The risk of VT/VF and sudden death suggests that ICDs rather than pacemakers should be considered for these patients. (J Cardiovasc Electrophysiol, Vol. 22, pp. 1369‐1375, December 2011)Keywords
This publication has 26 references indexed in Scilit:
- Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1American Heart Journal, 2010
- Electrocardiographic Abnormalities and Sudden Death in Myotonic Dystrophy Type 1New England Journal of Medicine, 2008
- ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm AbnormalitiesCirculation, 2008
- Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacingJACC, 2002
- 99th ENMC international workshop: myotonic dystrophy: present management, future therapyNeuromuscular Disorders, 2002
- New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1)Neurology, 2000
- Mechanisms of Sustained Ventricular Tachycardia in Myotonic DystrophyCirculation, 1998
- Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family memberCell, 1992
- Population frequencies of inherited neuromuscular diseases—A world surveyNeuromuscular Disorders, 1991
- Pathology of the cardiac conduction system in myotonic dystrophy: A study of 12 casesJACC, 1988